EUCTR2014-002240-40-GB进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 616
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Have a histopathologically confirmed diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. All histologies of nonsquamous cell origin including undifferentiated gastric carcinoma are eligible.
- •Have not received any prior first-line systemic therapy (prior adjuvant or neo-adjuvant therapy is permitted). Participants whose disease has progressed after >12 months following the last dose of systemic treatment in the adjuvant/neoadjuvant setting are eligible.
- •Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
- •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale at baseline.
- •Have adequate organ function.
- •Have baseline clinical and laboratory parameters that are consistent with the requirements prescribed in respective labels and are suitable for consideration of treatment with capecitabine (or 5-FU) and cisplatin (for example, dihydropyrimidine dehydrogenase deficiency).
- •Have an estimated life expectancy of =12 weeks in the judgment of the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 370
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 246
排除标准
- •Participants with adenocarcinoma of the esophagus are excluded.
- •Participants with human epidermal growth factor receptor 2 (HER2)-positive status.
- •Participants receiving chronic therapy with nonsteroidal anti-inflammatory agents.
- •Have radiation therapy within 14 days prior to randomization.
- •Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cord compression.
- •Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within 12 weeks prior to randomization.
- •Have experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization.
- •Have symptomatic congestive heart failure (New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
- •Have uncontrolled hypertension prior to initiating study treatment, despite antihypertensive intervention.
- •Have undergone major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to first dose of study treatment, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter [PICC] line) and the investigator does not anticipate any significant bleeding.
- •Have a history of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
- •Have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =12 months prior to randomization.
- •Have an acute or subacute bowel obstruction or history of chronic diarrhea which is considered clinically significant in the opinion of the investigator.
- •The participant has:
- •ocirrhosis at a level of Child-Pugh B (or worse) or
- •ocirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
- •Have known allergy or hypersensitivity to any components of study treatment.
- •Are pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Blisibimod in IgA NephropathyEUCTR2014-001365-26-ESAnthera pharmaceuticals, Inc200
进行中（未招募）
1 期
Vedolizumab IV 300 mg in the Treatment of Chronic PouchitisEUCTR2015-003472-78-GBTakeda Development Centre Europe, Ltd.110
进行中（未招募）
1 期
A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host diseaseEUCTR2017-000538-78-PTIncyte Corporation436
进行中（未招募）
1 期
A Study of BLU-263 in patients with Indolent Systemic MastocytosisIndolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)MedDRA version: 27.0Level: PTClassification code 10056452Term: Indolent systemic mastocytosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005173-28-ATBlueprint Medicines Corporation463
进行中（未招募）
1 期
A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host diseaseEUCTR2017-000538-78-ATIncyte Corporation436